188 related articles for article (PubMed ID: 20922911)
1. Levofloxacin prophylaxis to prevent bacterial infection in chemotherapy-induced neutropenia in acute leukemia.
Rahman MM; Khan MA
Bangladesh Med Res Counc Bull; 2009 Dec; 35(3):91-4. PubMed ID: 20922911
[TBL] [Abstract][Full Text] [Related]
2. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia.
Bucaneve G; Micozzi A; Menichetti F; Martino P; Dionisi MS; Martinelli G; Allione B; D'Antonio D; Buelli M; Nosari AM; Cilloni D; Zuffa E; Cantaffa R; Specchia G; Amadori S; Fabbiano F; Deliliers GL; Lauria F; Foà R; Del Favero A;
N Engl J Med; 2005 Sep; 353(10):977-87. PubMed ID: 16148283
[TBL] [Abstract][Full Text] [Related]
3. Antibacterial prophylaxis after chemotherapy for solid tumors and lymphomas.
Cullen M; Steven N; Billingham L; Gaunt C; Hastings M; Simmonds P; Stuart N; Rea D; Bower M; Fernando I; Huddart R; Gollins S; Stanley A;
N Engl J Med; 2005 Sep; 353(10):988-98. PubMed ID: 16148284
[TBL] [Abstract][Full Text] [Related]
4. A comparison of levofloxacin and oral third-generation cephalosporins as antibacterial prophylaxis in acute leukaemia patients during chemotherapy-induced neutropenia.
Yemm KE; Barreto JN; Mara KC; Dierkhising RA; Gangat N; Tosh PK
J Antimicrob Chemother; 2018 Jan; 73(1):204-211. PubMed ID: 29040595
[TBL] [Abstract][Full Text] [Related]
5. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Reuter S; Kern WV; Sigge A; Döhner H; Marre R; Kern P; von Baum H
Clin Infect Dis; 2005 Apr; 40(8):1087-93. PubMed ID: 15791505
[TBL] [Abstract][Full Text] [Related]
6. Moxifloxacin versus levofloxacin or ciprofloxacin prophylaxis in acute myeloid leukemia patients receiving chemotherapy.
Przybylski DJ; Reeves DJ
Support Care Cancer; 2017 Dec; 25(12):3715-3721. PubMed ID: 28660351
[TBL] [Abstract][Full Text] [Related]
7. [Clinical study on fluoroquinolone prophylaxis in neutropenia patients with acute leukemia].
Qin TJ; Mi YC; Feng SZ; Li DP; Wei JL; Yang DL; Han MZ; Wang JX; Bian SG
Zhonghua Yi Xue Za Zhi; 2007 May; 87(20):1389-93. PubMed ID: 17785058
[TBL] [Abstract][Full Text] [Related]
8. Antibiotic prophylaxis in chemotherapy-induced neutropenia: time to reconsider.
Lo N; Cullen M
Hematol Oncol; 2006 Sep; 24(3):120-5. PubMed ID: 16783844
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin versus levofloxacin for antibacterial prophylaxis in acute leukemia patients.
Lee P; Knoebel RW; Pisano J; Pettit NN
J Oncol Pharm Pract; 2019 Apr; 25(3):758-761. PubMed ID: 29310512
[TBL] [Abstract][Full Text] [Related]
10. Rational selection of patients for antibacterial prophylaxis after chemotherapy.
Cullen MH; Billingham LJ; Gaunt CH; Steven NM
J Clin Oncol; 2007 Oct; 25(30):4821-8. PubMed ID: 17947731
[TBL] [Abstract][Full Text] [Related]
11. Levofloxacin Prophylaxis During Induction Therapy for Pediatric Acute Lymphoblastic Leukemia.
Wolf J; Tang L; Flynn PM; Pui CH; Gaur AH; Sun Y; Inaba H; Stewart T; Hayden RT; Hakim H; Jeha S
Clin Infect Dis; 2017 Nov; 65(11):1790-1798. PubMed ID: 29020310
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase III trial of docetaxel plus carboplatin with or without levofloxacin prophylaxis in elderly patients with advanced non-small cell lung cancer: the APRONTA trial.
Schuette W; Nagel S; von Weikersthal LF; Pabst S; Schumann C; Deuss B; Salm T; Roscher K; Dickgreber N
J Thorac Oncol; 2011 Dec; 6(12):2090-6. PubMed ID: 22052225
[TBL] [Abstract][Full Text] [Related]
13. Levofloxacin vs. ciprofloxacin plus phenethicillin for the prevention of bacterial infections in patients with haematological malignancies.
Timmers GJ; Simoons-Smit AM; Leidekker ME; Janssen JJ; Vandenbroucke-Grauls CM; Huijgens PC
Clin Microbiol Infect; 2007 May; 13(5):497-503. PubMed ID: 17263835
[TBL] [Abstract][Full Text] [Related]
14. Comparison of antibiotic prophylaxis with cotrimoxazole/colistin (COT/COL) versus ciprofloxacin (CIP) in patients with acute myeloid leukemia.
Mayer K; Hahn-Ast C; Mückter S; Schmitz A; Krause S; Felder L; Bekeredjian-Ding I; Molitor E; Brossart P; von Lilienfeld-Toal M
Support Care Cancer; 2015 May; 23(5):1321-9. PubMed ID: 25617073
[TBL] [Abstract][Full Text] [Related]
15. Antibiotic prophylaxis in neutropenic patients: new evidence, practical decisions.
Leibovici L; Paul M; Cullen M; Bucaneve G; Gafter-Gvili A; Fraser A; Kern WV
Cancer; 2006 Oct; 107(8):1743-51. PubMed ID: 16977651
[TBL] [Abstract][Full Text] [Related]
16. Effect of Levofloxacin Prophylaxis on Bacteremia in Children With Acute Leukemia or Undergoing Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.
Alexander S; Fisher BT; Gaur AH; Dvorak CC; Villa Luna D; Dang H; Chen L; Green M; Nieder ML; Fisher B; Bailey LC; Wiernikowski J; Sung L;
JAMA; 2018 Sep; 320(10):995-1004. PubMed ID: 30208456
[TBL] [Abstract][Full Text] [Related]
17. Levofloxacin for febrile neutropenia prophylaxis in acute myeloid leukemia patients associated with reduction in hospital admissions.
Lee SSF; Fulford AE; Quinn MA; Seabrook J; Rajakumar I
Support Care Cancer; 2018 May; 26(5):1499-1504. PubMed ID: 29170868
[TBL] [Abstract][Full Text] [Related]
18. Ciprofloxacin versus colistin prophylaxis during neutropenia in acute myeloid leukemia: two parallel patient cohorts treated in a single center.
Pohlen M; Marx J; Mellmann A; Becker K; Mesters RM; Mikesch JH; Schliemann C; Lenz G; Müller-Tidow C; Büchner T; Krug U; Stelljes M; Karch H; Peters G; Gerth HU; Görlich D; Berdel WE
Haematologica; 2016 Oct; 101(10):1208-1215. PubMed ID: 27470601
[TBL] [Abstract][Full Text] [Related]
19. Safe fluoroquinolones prophylaxis in blood cancer patients with chemotherapy-induced neutropenia and Glucose-6-Phosphate-Dehydrogenase deficiency.
Sanna M; Caocci G; Orrù F; Ledda A; Vacca A; Piras E; Fozza C; Deias P; Tidore G; Dore F; La Nasa G
J Clin Pharm Ther; 2017 Dec; 42(6):733-737. PubMed ID: 28597476
[TBL] [Abstract][Full Text] [Related]
20. Obesity is not strongly associated with increased risk for febrile neutropenia during levofloxacin prophylaxis in patients with hematological malignancies receiving intermediate-risk myelosuppressive chemotherapy.
Kurtti A; Fritz K; Elofson-Disney K; Benefield R
J Oncol Pharm Pract; 2020 Sep; 26(6):1301-1305. PubMed ID: 31810423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
